Zoetis Inc. (NYSE:ZTS) Shares Bought by Retirement Planning Co of New England Inc.

Retirement Planning Co of New England Inc. raised its holdings in Zoetis Inc. (NYSE:ZTS) by 19.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,189 shares of the company’s stock after acquiring an additional 349 shares during the period. Retirement Planning Co of New England Inc.’s holdings in Zoetis were worth $357,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Callahan Advisors LLC raised its holdings in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after acquiring an additional 6,221 shares during the last quarter. Pensionfund Sabic grew its stake in shares of Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after buying an additional 4,000 shares during the period. CIBC Asset Management Inc grew its stake in shares of Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after buying an additional 46,050 shares during the period. PFW Advisors LLC purchased a new stake in shares of Zoetis in the 4th quarter valued at approximately $1,764,000. Finally, Alberta Investment Management Corp grew its stake in shares of Zoetis by 2,050.0% in the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock valued at $4,904,000 after buying an additional 28,700 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock valued at $312,254 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the subject of several analyst reports. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Barclays increased their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average target price of $215.90.

Zoetis Stock Performance

Shares of ZTS stock opened at $165.39 on Tuesday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The stock has a market capitalization of $74.06 billion, a PE ratio of 30.24, a P/E/G ratio of 2.78 and a beta of 0.94. The firm has a 50 day moving average of $166.82 and a two-hundred day moving average of $175.97.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. On average, research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.21%. Zoetis’s dividend payout ratio is presently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.